Hello everyone, I am new to the sequencing world and just joined this forum.
We would like to do whole transcriptome sequencing on human tissue in order to identify (new) splice variants and fusion transcripts to see how they are associated with outcome in a particular cancer.
I have seen there are different approaches using either mapping to a reference genome or de novo assembly.
What is the advantage of using the de novo assembly strategy?
Given the requirements for computational power is it worth going the de novo assembly route?
Thanks for your input,
O.
We would like to do whole transcriptome sequencing on human tissue in order to identify (new) splice variants and fusion transcripts to see how they are associated with outcome in a particular cancer.
I have seen there are different approaches using either mapping to a reference genome or de novo assembly.
What is the advantage of using the de novo assembly strategy?
Given the requirements for computational power is it worth going the de novo assembly route?
Thanks for your input,
O.
Comment